Clinical trial

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-12-06

PhasePHASE4

Study timeline

Study start (actual)2022-12-06Date precision: day

Registry last updated2025-12-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 1 Diabetesunresolved

Interventions

Evolocumab CartridgeDRUG · verified · RxNorm: evolocumab Cartridge

Atorvastatin Calcium TabletsDRUG

Ezetimibe TabletsDRUG

Angiocatheter 20IVDEVICE

J-WireDEVICE

GlycoCheck Glycocalyx Measurement SoftwareDEVICE

Sponsors & collaborators

NYU Langone Healthlead sponsor

National Heart, Lung, and Blood Institute (NHLBI)collaborator

Mapped research locations

New YorkNew York, United States4

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05641753 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.